Trial · NCT02507284

Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease

NCT02507284, Phase 2, Completed, Azevan Pharmaceuticals; results first posted 2023-07-20

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease. Trials, record NCT02507284. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02507284

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease
NCT number: NCT02507284
Status: Completed
Phases: Phase 2
Enrollment: 106 participants, actual
Lead sponsor: Azevan Pharmaceuticals
Conditions: Irritable Mood, Huntington's Disease
Interventions: SRX246, Placebo
First posted: 2015-07-23
Last updated: 2023-07-20
Results first posted: 2023-07-20

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Tolerability of SRX246	12 weeks	The primary endpoint, tolerability of SRX246, was assessed by the number of completers in each group.
Secondary	Safety of SRX246	12 weeks	The Safety of SRX246 was assessed by the number of participants who experience an adverse event.

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Tolerability of SRX246	12 weeks		Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Safety of SRX246	12 weeks		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Units
Tolerability of SRX246	SRX246 120mg BID	25	Participants
Tolerability of SRX246	SRX246 160mg BID	27	Participants
Tolerability of SRX246	Placebo	30	Participants
Safety of SRX246	SRX246 120mg BID	29	Participants
Safety of SRX246	SRX246 160mg BID	30	Participants
Safety of SRX246	Placebo	26	Participants

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	SRX246 120mg BID	36
Overall Study	STARTED	SRX246 160mg BID	34
Overall Study	STARTED	Placebo	36
Overall Study	COMPLETED	SRX246 120mg BID	25
Overall Study	COMPLETED	SRX246 160mg BID	27
Overall Study	COMPLETED	Placebo	30
Overall Study	NOT COMPLETED	SRX246 120mg BID	11
Overall Study	NOT COMPLETED	SRX246 160mg BID	7
Overall Study	NOT COMPLETED	Placebo	6

Source ClinicalTrials.gov

Adverse events33

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	nausea	Gastrointestinal disorders	SRX246 120mg BID	7	36	13
other	nausea	Gastrointestinal disorders	SRX246 160mg BID	9	34	13
other	nausea	Gastrointestinal disorders	Placebo	4	36	4
other	Fatigue	General disorders	SRX246 120mg BID	3	36	3
other	Fatigue	General disorders	SRX246 160mg BID	5	34	7
other	Fatigue	General disorders	Placebo	2	36	2
other	Upper Respiratory Tract Infection	Infections and infestations	SRX246 120mg BID	6	36	7
other	Upper Respiratory Tract Infection	Infections and infestations	SRX246 160mg BID	4	34	4
other	Upper Respiratory Tract Infection	Infections and infestations	Placebo	9	36	11
other	Fall	Injury, poisoning and procedural complications	SRX246 120mg BID	4	36	6

1 to 10 of 33Source ClinicalTrials.gov

See all 33 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	SRX246 120mg BID	0	36
Total, all-cause mortality	SRX246 160mg BID	0	34
Total, all-cause mortality	Placebo	0	36
Total, other adverse events	SRX246 120mg BID	29	36
Total, other adverse events	SRX246 160mg BID	30	34
Total, other adverse events	Placebo	26	36
Total, serious adverse events	SRX246 120mg BID	5	36
Total, serious adverse events	SRX246 160mg BID	0	34
Total, serious adverse events	Placebo	0	36

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U44NS090616	Tolerability of SRX246 in Huntington's Disease Patients	BROWNSTEIN, MICHAEL J; COFFEY, CHRISTOPHER S.; CUDKOWICZ, MERIT E; HERSCH, STEVEN M	AZEVAN PHARMACEUTICALS, INC.	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE	2015 to 2018

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02507284

GET https://conductscience.org/api/trials/v1/NCT02507284/events?page=2

API reference For AI assistants